<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>66</volume><submitter>Luna-Marco C</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Type 2 diabetes (T2D) is linked to metabolic, mitochondrial and inflammatory alterations, atherosclerosis development and cardiovascular diseases (CVDs). The aim was to investigate the potential therapeutic benefits of GLP-1 receptor agonists (GLP-1 RA) on oxidative stress, mitochondrial respiration, leukocyte-endothelial interactions, inflammation and carotid intima-media thickness (CIMT) in T2D patients.&lt;h4>Research design and methods&lt;/h4>Type 2 diabetic patients (255) and control subjects (175) were recruited, paired by age and sex, and separated into two groups: without GLP-1 RA treatment (196) and treated with GLP-1 RA (59). Peripheral blood polymorphonuclear leukocytes (PMNs) were isolated to measure reactive oxygen species (ROS) production by flow cytometry and oxy</pubmed_abstract><journal>Redox biology</journal><pagination>102849</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10457591</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes.</pubmed_title><pmcid>PMC10457591</pmcid><pubmed_authors>Rocha M</pubmed_authors><pubmed_authors>Sola E</pubmed_authors><pubmed_authors>de Maranon AM</pubmed_authors><pubmed_authors>Rodriguez-Hernandez Y</pubmed_authors><pubmed_authors>Vila J</pubmed_authors><pubmed_authors>Fernandez-Reyes M</pubmed_authors><pubmed_authors>Rovira-Llopis S</pubmed_authors><pubmed_authors>Morillas C</pubmed_authors><pubmed_authors>Luna-Marco C</pubmed_authors><pubmed_authors>Apostolova N</pubmed_authors><pubmed_authors>Victor VM</pubmed_authors><pubmed_authors>Hermenejildo J</pubmed_authors><pubmed_authors>Hermo-Argibay A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes.</name><description>&lt;h4>Objective&lt;/h4>Type 2 diabetes (T2D) is linked to metabolic, mitochondrial and inflammatory alterations, atherosclerosis development and cardiovascular diseases (CVDs). The aim was to investigate the potential therapeutic benefits of GLP-1 receptor agonists (GLP-1 RA) on oxidative stress, mitochondrial respiration, leukocyte-endothelial interactions, inflammation and carotid intima-media thickness (CIMT) in T2D patients.&lt;h4>Research design and methods&lt;/h4>Type 2 diabetic patients (255) and control subjects (175) were recruited, paired by age and sex, and separated into two groups: without GLP-1 RA treatment (196) and treated with GLP-1 RA (59). Peripheral blood polymorphonuclear leukocytes (PMNs) were isolated to measure reactive oxygen species (ROS) production by flow cytometry and oxy</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2025-04-18T18:48:22.221Z</modification><creation>2025-04-07T06:27:52.01Z</creation></dates><accession>S-EPMC10457591</accession><cross_references><pubmed>37591012</pubmed><doi>10.1016/j.redox.2023.102849</doi></cross_references></HashMap>